Palvella Therapeutics (PVLA) Competitors $20.51 +0.44 (+2.19%) As of 04/8/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock PVLA vs. CALT, OCUL, ARDX, WVE, PCRX, EVO, INVA, AUPH, DYN, and SNDXShould you be buying Palvella Therapeutics stock or one of its competitors? The main competitors of Palvella Therapeutics include Calliditas Therapeutics AB (publ) (CALT), Ocular Therapeutix (OCUL), Ardelyx (ARDX), Wave Life Sciences (WVE), Pacira BioSciences (PCRX), Evotec (EVO), Innoviva (INVA), Aurinia Pharmaceuticals (AUPH), Dyne Therapeutics (DYN), and Syndax Pharmaceuticals (SNDX). These companies are all part of the "pharmaceutical preparations" industry. Palvella Therapeutics vs. Calliditas Therapeutics AB (publ) Ocular Therapeutix Ardelyx Wave Life Sciences Pacira BioSciences Evotec Innoviva Aurinia Pharmaceuticals Dyne Therapeutics Syndax Pharmaceuticals Palvella Therapeutics (NASDAQ:PVLA) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation. Is PVLA or CALT more profitable? Palvella Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Palvella Therapeutics' return on equity of -80.93% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Palvella TherapeuticsN/A -80.93% -59.55% Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96% Do analysts rate PVLA or CALT? Palvella Therapeutics presently has a consensus price target of $43.50, indicating a potential upside of 112.09%. Calliditas Therapeutics AB (publ) has a consensus price target of $39.25, indicating a potential downside of 1.88%. Given Palvella Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Palvella Therapeutics is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Palvella Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Calliditas Therapeutics AB (publ) 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media favor PVLA or CALT? In the previous week, Palvella Therapeutics had 14 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 14 mentions for Palvella Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Palvella Therapeutics' average media sentiment score of 0.21 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Palvella Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Palvella Therapeutics Neutral Calliditas Therapeutics AB (publ) Neutral Which has preferable earnings and valuation, PVLA or CALT? Palvella Therapeutics has higher earnings, but lower revenue than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Palvella Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPalvella Therapeutics$42.81M5.28-$24.54M-$12.10-1.70Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62 Does the MarketBeat Community prefer PVLA or CALT? Calliditas Therapeutics AB (publ) received 15 more outperform votes than Palvella Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Palvella Therapeutics an outperform vote while only 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote. CompanyUnderperformOutperformPalvella TherapeuticsOutperform Votes12100.00% Underperform VotesNo VotesCalliditas Therapeutics AB (publ)Outperform Votes2755.10% Underperform Votes2244.90% Which has more volatility & risk, PVLA or CALT? Palvella Therapeutics has a beta of 0.1, suggesting that its stock price is 90% less volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500. Do insiders and institutionals hold more shares of PVLA or CALT? 40.1% of Palvella Therapeutics shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 6.4% of Palvella Therapeutics shares are owned by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryPalvella Therapeutics beats Calliditas Therapeutics AB (publ) on 14 of the 19 factors compared between the two stocks. Remove Ads Get Palvella Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PVLA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PVLA vs. The Competition Export to ExcelMetricPalvella TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$226M$6.07B$5.08B$6.91BDividend YieldN/A2.87%5.33%4.20%P/E Ratio-1.706.5321.3317.05Price / Sales5.28185.42349.5885.95Price / CashN/A65.6738.1534.64Price / Book0.955.356.053.66Net Income-$24.54M$141.19M$3.19B$247.27M7 Day Performance-13.06%-10.64%-7.80%-8.86%1 Month Performance-16.46%-20.11%-6.79%-12.84%1 Year PerformanceN/A-22.14%0.32%-10.80% Palvella Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PVLAPalvella Therapeutics3.0634 of 5 stars$20.51+2.2%$43.50+112.1%N/A$226M$42.81M-1.70N/AGap DownCALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180OCULOcular Therapeutix2.8989 of 5 stars$7.34+12.2%$16.38+123.1%-24.7%$1.17B$63.72M-5.56230Analyst ForecastNews CoveragePositive NewsGap DownARDXArdelyx4.1839 of 5 stars$4.88+1.9%$10.95+124.4%-40.8%$1.16B$333.62M-30.5090Insider TradeNews CoverageGap UpWVEWave Life Sciences4.4525 of 5 stars$7.57-2.2%$22.60+198.5%-3.4%$1.16B$108.30M-6.82240Analyst ForecastGap UpPCRXPacira BioSciences2.4882 of 5 stars$24.89+3.4%$27.22+9.4%-7.8%$1.15B$700.97M-12.26720Analyst ForecastNews CoverageGap UpEVOEvotec1.4003 of 5 stars$3.23-3.3%$5.93+83.7%-61.4%$1.14B$777.05M0.004,200News CoverageGap UpINVAInnoviva4.2628 of 5 stars$18.07+0.7%$55.00+204.4%+17.1%$1.13B$358.71M26.19100Positive NewsAUPHAurinia Pharmaceuticals2.6181 of 5 stars$8.19+1.7%$11.50+40.4%+44.6%$1.12B$235.13M-54.60300News CoverageDYNDyne Therapeutics3.1366 of 5 stars$9.91+7.4%$47.46+378.9%-74.7%$1.12BN/A-2.78100News CoverageGap UpSNDXSyndax Pharmaceuticals3.3575 of 5 stars$12.97+8.0%$36.20+179.1%-53.7%$1.12B$23.68M-3.57110News CoverageGap Up Remove Ads Related Companies and Tools Related Companies CALT Competitors OCUL Competitors ARDX Competitors WVE Competitors PCRX Competitors EVO Competitors INVA Competitors AUPH Competitors DYN Competitors SNDX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PVLA) was last updated on 4/9/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Silver isn't just a safe haven for your wealth—it's a critical resource in the global tech and energy race. Wi...GoldenCrest Metals | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | SponsoredElon’s Silver Play? Trump Clears the PathNothing is confirmed—yet. But Musk has disrupted every industry he's touched, and Trump's policies make the ti...Priority Gold | SponsoredThinking of buying Nvidia? Read this firstI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palvella Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Palvella Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PVLA Stock Free PVLA Stock Alerts